The estimated Net Worth of Eric Benevich is at least $21.8 Milione dollars as of 15 April 2024. Mr. Benevich owns over 19,818 units of Neurocrine Biosciences stock worth over $6,482,247 and over the last 9 years he sold NBIX stock worth over $9,513,650. In addition, he makes $5,793,450 as Chief Commercial Officer at Neurocrine Biosciences.
Sign up
Mr. Benevich NBIX stock SEC Form 4 insiders trading
Eric has made over 30 trades of the Neurocrine Biosciences stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 19,818 units of NBIX stock worth $1,609,420 on 15 April 2024.
The largest trade he's ever made was exercising 75,000 units of Neurocrine Biosciences stock on 14 March 2024 worth over $6,067,500. On average, Eric trades about 10,840 units every 77 days since 2015. As of 15 April 2024 he still owns at least 53,365 units of Neurocrine Biosciences stock.
You can see the complete history of Mr. Benevich stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Benevich biography
Eric S. Benevich serves as Chief Commercial Officer of the Company. He was was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing and sales of the Neurocrine Biosciences product portfolio. Previously, Mr. Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015, serving most recently as Vice President of Marketing where he was responsible for NUEDEXTA ® and commercialization of their CNS pipeline. Mr. Benevich has over 20 years of experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel ® , Epogen ® and Prilosec ® . Mr. Benevich has a BBA in International Business from Washington State University.
What is the salary of Eric Benevich?
As the Chief Commercial Officer of Neurocrine Biosciences, the total compensation of Eric Benevich at Neurocrine Biosciences is $5,793,450. There are 2 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.
How old is Eric Benevich?
Eric Benevich is 54, he's been the Chief Commercial Officer of Neurocrine Biosciences since 2015. There are 15 older and 6 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
What's Eric Benevich's mailing address?
Eric's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Insiders trading at Neurocrine Biosciences
Over the last 21 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... e Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
What does Neurocrine Biosciences do?
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
What does Neurocrine Biosciences's logo look like?
Complete history of Mr. Benevich stock trades at Neurocrine Biosciences
Neurocrine Biosciences executives and stock owners
Neurocrine Biosciences executives and other stock owners filed with the SEC include:
-
Kevin Gorman,
Chief Executive Officer, Director -
Matthew Abernethy,
Chief Financial Officer -
Eric Benevich,
Chief Commercial Officer -
Eiry Roberts,
Chief Medical Officer -
Haig Bozigian,
Chief Development Officer -
Kyle Gano,
Chief Business Development and Strategy Officer -
Dimitri Grigoriadis,
Chief Research Officer -
Dr. Kevin C. Gorman Ph.D.,
CEO & Director -
Dr. Eiry Wyn Roberts,
Chief Medical Officer -
Leslie Norwalk,
Independent Director -
Matthew C. Abernethy,
Chief Financial Officer -
Eric S. Benevich,
Chief Commercial Officer -
Kyle W. Gano,
Chief Bus. Devel. and Strategy Officer -
William Rastetter,
Independent Chairman of the Board -
Stephen Sherwin,
Independent Director -
Richard Pops,
Independent Director -
George Morrow,
Independent Director -
Gary Lyons,
Independent Director -
Todd Tushla,
Investor Relations -
Julie Cooke,
Chief Human Resource Officer -
Shalini Sharp,
Independent Director -
Darin Lippoldt,
Chief Legal Officer and Corporate Secretary -
Malcolm Lloyd-Smith,
Chief Regulatory Officer -
David Boyer,
Chief Corporate Affairs Officer -
Julie S. Cooke,
Chief HR Officer -
Darin M. Lippoldt,
Chief Legal Officer & Corp. Sec. -
Jane Sorensen,
Head of Investor Relations -
Dr. Jude Onyia Ph.D.,
Chief Scientific Officer -
Dr. Dimitri E. Grigoriadis,
Chief Research Officer -
Matt Abernethy,
Chief Financial Officer -
Corinne H Nevinny,
Director -
Christopher Flint O Brien,
Sr. VP & Chief Medical Officer -
Joseph A Mollica,
Director -
David Alexandre C Gros,
President & COO -
Alfred Sandrock,
Director -
Christine A Poon,
Director -
Wylie W Vale,
Director -
Timothy Coughlin,
VP and Chief Financial Officer -
Jensen Margaret E Valeur,
Senior VP and General Counsel -
Partners L P/Ilbiotechnolog...,
-
Johanna Mercier,
Director -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Henry Pan,
Executive VP and CMO -
Wendall Wierenga,
EVP, Research & Development -
Richard J Ranieri,
Sr. VP, Human Resources -
Thomas Mitchell W,
Director -
Ingrid Delaet,
Chief Regulatory Officer -
Paul W Hawran,
Executive VP and CFO -
Paul J Conlon,
Vice President Research (Biol) -
Lawrence Steinman,
Director -
John Saunders,
Vice President Research (Chem) -
Robert J Little,
SVP, Commercial Operations -
D Bruce Campbell,
Senior Vice President -
Jude Onyia,
Chief Scientific Officer